Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
1 finding from 1 review
Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic evaluation ‐ not measured · women with recurrent or FIGO stage IVB cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcome domain · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ CAT · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · COPD and at least one other long‐term condition
1 finding from 1 review
Quality of life ‐ CAT · COPD and at least one other long‐term condition
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · COPD and at least one other long‐term condition
It is very uncertain whether intervention changes exacerbations ‐ number of people experiencing one or more  compared with usual care (very low certainty).
1 finding from 1 review
Hospital admissions · COPD and at least one other long‐term condition
Intervention showed no clear difference in all‐cause hospital admissions ‐ people experiencing one or more  compared with usual care (low certainty).
1 finding from 1 review
All‐cause mortality (deaths) Â · COPD and at least one other long‐term condition
It is very uncertain whether intervention changes all‐cause mortality (deaths) Â compared with usual care (very low certainty).
1 finding from 1 review
Outcome domain · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · COPD and at least one other long‐term condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All intervention options · people with first recurrence of glioblastoma Interventions: bevacizumab (BEV), BEV + lomustine (LOM), regorafenib (REG), fotemustine…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+IRI (1 RCT, 79 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).
1 finding from 1 review